Abstract:ABSTRACT Antibiotic-resistant Gram-negative bacteria remain a globally leading cause of bacterial infection-associated mortality, and it is imperative to identify novel therapeutic strategies. Recently, the advantage of using antibacterials selective against Gram-negative bacteria has been demonstrated with polymyxins that specifically target the lipopolysaccharides of Gram-negative bacteria. However, the severe cytotoxicity of polymyxins limits their clinical use. Here, we demonstrate that polymyxin B nonapeptide (PMBN), a polymyxin B derivative without the terminal amino acyl residue, can significantly enhance the effectiveness of commonly used antibiotics against only Gram-negative bacteria and their persister cells. We show that although PMBN itself does not exhibit antibacterial activity or cytotoxicity well above the 100-fold minimum inhibitory concentration of polymyxin B, PMBN can increase the potency of co-treated antibiotics. We also demonstrate that using PMBN in combination with other antibiotics significantly reduces the frequency of resistant mutant formation. Together, this work provides evidence of the utilities of PMBN as a novel potentiator for antibiotics against Gram-negative bacteria and insights for the eradication of bacterial persister cells during antibiotic treatment. IMPORTANCE The significance of our study lies in addressing the problem of antibiotic-resistant Gram-negative bacteria, which continue to be a global cause of mortality associated with bacterial infections. Therefore, identifying innovative therapeutic approaches is an urgent need. Recent research has highlighted the potential of selective antibacterials like polymyxins, which specifically target the lipopolysaccharides of Gram-negative bacteria. However, the clinical use of polymyxins is limited by their severe cytotoxicity. This study unveils the effectiveness of polymyxin B nonapeptide (PMBN) in significantly enhancing the eradication of persister cells in Gram-negative bacteria. Although PMBN itself does not exhibit antibacterial activity or cytotoxicity, it remarkably reduces persister cells during the treatment of antibiotics. Moreover, combining PMBN with other antibiotics reduces the emergence of resistant mutants. Our research emphasizes the utility of PMBN as a novel potentiator to decrease persister cells during antibiotic treatments for Gram-negative bacteria.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the treatment dilemma of antibiotic - resistant Gram - negative bacterial infections. Specifically, the research focuses on how to effectively eliminate persister cells in these bacteria and how to reduce the formation of antibiotic - resistant mutants. These problems have led to an increase in mortality related to bacterial infections on a global scale, so there is an urgent need to develop new treatment strategies. The paper proposes that Polymyxin B nonapeptide (PMBN), as a derivative of Polymyxin B, can significantly enhance the effects of commonly used antibiotics on Gram - negative bacteria and their persister cells without showing its own antibacterial activity or cytotoxicity. In addition, the research also shows that the combined use of PMBN and other antibiotics can significantly reduce the frequency of resistant mutants. In conclusion, this study provides evidence for PMBN as a new antibiotic potentiator, which helps to more effectively eliminate persister cells of Gram - negative bacteria during antibiotic treatment and provides new insights into reducing the formation of resistant mutants.

Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters

Polymyxin B in Combination with Glycerol Monolaurate Exerts Synergistic Killing against Gram-Negative Pathogens

Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria

A cyclic adenosine monophosphate response element-binding protein inhibitor enhances the antibacterial activity of polymyxin B by inhibiting the ATP hydrolyzation activity of CrrB

Exploitation of a novel adjuvant for polymyxin B against multidrug-resistant Acinetobacter baumannii

Efficiency of Polymyxin B Treatment Against Nosocomial Infection: a Systematic Review and Meta-Analysis

Polymyxin B adjuvants against polymyxin B- and carbapenem-resistant Gram-negative bacteria

Polymyxin B and Fusidic Acid, a Novel Potent Synergistic Combination Against Klebsiella Pneumoniae and Escherichia Coli Isolates with Polymyxin B Resistance

Design, synthesis, and bioactivity investigation of novel cyclic lipopeptide antibiotics targeting top-priority multidrug-resistant gram-negative bacteria

A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria

Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli

A method for increasing electroporation competence of Gram-negative clinical isolates by polymyxin B nonapeptide

Polymyxins retain in vitro activity and in vivo efficacy against "resistant" Acinetobacter baumannii strains when tested in physiological conditions

Antibacterial Activity of Polymyxins Encapsulated in Nanocarriers Against Gram-Negative Bacteria

Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity

Unveiling synergism of polymyxin B with chloramphenicol derivatives against multidrug-resistant (MDR) Klebsiella pneumoniae

Polymyxin B1 in the Escherichia coli inner membrane: A complex story of protein and lipopolysaccharide-mediated insertion

Peptide-mimicking poly(2-oxazoline)s as adjuvants to enhance activities and antibacterial spectrum of polymyxin B

Polymyxin B-Polysaccharide Polyion Nanocomplex with Improved Biocompatibility and Unaffected Antibacterial Activity for Acute Lung Infection Management

Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii